Trials / Completed
CompletedNCT00795158
How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)
An Open-Label Study of the Effects of Desloratadine Treatment on the Quality of Life of Patients With Chronic Urticaria
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 282 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the effect of desloratadine treatment on quality of life, daytime functioning, quality of sleep, symptoms, and disease severity in patients who had hives for 6 weeks or longer. Patients took desloratadine for 1 month. Once a week, patients filled out a questionnaire to tell how their hives affected their lives. This questionnaire is called the Dermatology Life Quality Index or DLQI. They also filled out a diary every day to tell how much itching they had, how many hives they had, and how their hives had affected their sleep or daily activities. The patients and doctors rated the patients' overall condition and how much relief patients got from treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | desloratadine | desloratadine 5 mg tablets; one tablet orally once a day for 28 days |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2004-01-01
- Completion
- 2004-01-01
- First posted
- 2008-11-21
- Last updated
- 2022-02-17
Source: ClinicalTrials.gov record NCT00795158. Inclusion in this directory is not an endorsement.